Upadacitinib Delivers Rapid Response in Ulcerative Colitis Upadacitinib Delivers Rapid Response in Ulcerative Colitis

Serious and severe adverse events, as well as higher rates of discontinuation due to treatment-related adverse events, were more common in the placebo group.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Gastroenterology News Source Type: news